A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor

Abstract

Solriamfetol appears to have abuse potential similar to or lower than phentermine.